Resumen

Hepatitis B virus (HBV) reactivation is a well-established complication of severe immunosuppression in patients with hematologic malignancy and positive hepatitis B surface antigen (HBsAg). Patients who receive high-dose chemotherapy, corticosteroids, rituximab, or have a bone marrow transplant are particularly at increased risk for HBV reactivation. However, limited information is available in the literature regarding HBV reactivation in patients with isolated anti-HBc, particularly in the setting of multiple myeloma (MM). We report two cases of HBV reactivation in MM patients with isolated anti-HBc positive with a rather atypical presentation. In conclusion, our cases highlight that clinicians need to be cognizant about this potentially fatal but preventable complication of chemotherapy and immunosuppression.

Palabras clave: Viral hepatitis chemotherapy bone marrow transplant hematologic malignancy.

2014-07-07   |   485 visitas   |   Evalua este artículo 0 valoraciones

Vol. 13 Núm.4. Julio-Agosto 2014 Pags. 461-465 Ann Hepatol 2014; 13(4)